

Anu's Laboratories Ltd IPO opens 12th May '08, Price band fixed at Rs. 200 to Rs. 210

The Company had started export of its products in the year 2002 to Israel followed by exports to other countries like Italy, Japan, France, USA and Singapore. Currently, its exports comprise of 19.97% of its total turnover.

New Delhi, Delhi, IND, 2008-05-06 18:07:39 (IndiaPRwire.com)

Anu's Laboratories Limited, engaged in the manufacture of basic, advanced intermediates and fine chemicals and supplying them to various drug manufacturers, proposes to enter the capital markets on 12th May 2008 with a public issue of 38,20,000 Equity shares of Rs 10 each through 100% book building process. The price band has been fixed at Rs 200 to Rs 210 per equity share of Rs 10 each and the issue closes on 15th May 2008. After allowing for reservation of 2,00,000 equity shares for eligible employees, the net issue to the public will be 36,20,000 equity shares, constituting 31.63% of the post issue paid-up capital of the company. The IPO has been graded by ICRA and has assigned 'ICRA IPO Grade 2' to the Initial Public Offering. Almondz Global Securities Ltd, is the BRLM and Karvy Computershare Pvt Ltd is the Registrar for the Issue. The Equity shares are proposed to be listed on BSE.

Anu's Laboratories Ltd was incorporated in 1996 for manufacture of Bulk Active Pharma Ingredients and Intermediates for drug molecules and was promoted by Mr. K. Hari Babu. Mr. N.S. Walimbe joined as co-promoter in 1997. The present manufacturing plant of Anu's Laboratories Limited is located at Chilakamarri Village, Shadnagar of Mehboobnagar district in Andhra Pradesh. The Company is engaged in manufacture of Basic & Advanced Intermediates and fine chemicals and is presently having manufacturing facilities for key intermediates like 2,4-Dichloro-5-Fluoro Acetophenone (DCFA) (an intermediate for synthesizing quinolone antibiotics like ciprofloxacin); Chlorohexanone (key intermediate in the manufacture of cardio vascular medicine) and Methyl-4 (4-Chloro 1 oxo butane) a, a Di-Methyl Acetate (an intermediate in the manufacture of Fexofenadine an anti allergic drug)..

The Company had started export of its products in the year 2002 to Israel followed by exports to other countries like Italy, Japan, France, USA and Singapore. Currently, its exports comprise of 19.97% of its total turnover.

The Company's total income during the Financial Year ended March 31, 2007 was Rs. 12,129.52 lakhs as against Rs. 9,533.93 lakhs in the Financial Year ended March 31, 2006 and the net profit during the corresponding period was Rs 1,359.15 lakhs against Rs. 557.25 lakhs respectively. The total income and the net profit for the nine months period ended December 31, 2007 were Rs. 11,382.26 lakhs and Rs. 1,312.36 lakhs respectively.

In order to diversify and expand its business activities by means of forward integration, the Company has decided to expand its operations by setting up a new plant for manufacturing of drug intermediates including Active Pharmaceutical Ingredients (APIs) at Vishakhapatnam at an estimated cost of Rs. 55.09 crores and setting up a pilot plant for carrying out Contract Research and Manufacturing (CRAM) at Vishakhapatnam at an estimated cost of Rs. 8.34 crores. The long term working capital requirements would be Rs. 16.67 crores. The Company plans to meet the aforesaid objects by means of issue proceeds and internal accruals.

- END -

About Anu's Laboratory

Anu's Laboratories Limited is proposing, subject to market conditions and other considerations, a public issue of the equity shares and has filed the Red Herring Prospectus with Registrar of Companies (ROC), Hyderabad. The Red Herring Prospectus is available on the website of SEBI at www.sebi.gov.in, the website of the Book Running Lead Manager at www.almondzglobal.com and the website of the Company at www.anulabs.com.

This press release does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any equity shares, nor shall it or any part of it nor the fact of its distribution form the basis of, or be relied on in connection with, any contract or investment decision.

The Equity Shares have not been and will not be registered under the US Securities Act ('the Securities Act') or any state securities laws in the United States and may not be issued or sold within the United States or to, or for the account or benefit of, 'U.S. persons' (as defined in Regulation S under the Securities Act), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act.

Any potential investor should note that investment in equity shares involves a high degree of risk. For details, see the section titled 'Risk Factors' of the Red Herring Prospectus, which has been filed with the Registrar of Companies.

For more information, Please contact:

Kunal Karn

PR executive - Concept PR

You can also visit www.conceptpr.com for more information.